Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...

Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...